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We have previously described a group of non-small cell lung carcinomas without morphological evidence of neo-angiogenesis.
In these tumours neoplastic cells ﬁll up the alveoli and the only vessels present appear to belong to the trapped alveolar septa.
In the present study we have characterised the phenotype of the vessels present in these non-angiogenic tumours, in normal
lung and in angiogenic non-small cell lung carcinomas. The vessels, identiﬁed by the expression of CD31, were scored as
mature when expressing the epitope LH39 in the basal membrane and as newly formed when expressing aVb3 on the
endothelial cells and/or lacking LH39 expression. In the nine putative non-angiogenic cases examined, the vascular phenotype
of all the vessels was the same as that of alveolar vessels in normal lung: LH39 positive and aVb3 variable or negative. Instead
in 104 angiogenic tumours examined, only a minority of vessels (mean 13.1%; range 0–60%) expressed LH39, while aVb3 (in
45 cases) was strongly expressed on many vessels (mean 55.5%; range 5–90%). We conclude that in putative non-angiogenic
tumours the vascular phenotype is that of normal vessels and there is no neo-angiogenesis. This type of cancer may be
resistant to some anti-angiogenic therapy and different strategies need to be developed.
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The nature and the role played by vessels in tumour growth
have been debated for the last 50 years. The original view that
tumours rely on pre-existing vessels has been overturned by
robust experimental work showing that the formation of new
vessels is crucial to tumour growth (Folkman, 1971, 1995). In
the words of Folkman (1990): ‘Once a tumour ‘take’ has
occurred, every increase in tumour cell population must be
preceded by an increase in new capillaries converging on the
tumour’.
However, there is now growing evidence that, in certain situa-
tions, tumours can also exploit pre-existing vessels. It has been
reported by the writers and others (Kolin and Koutoulakis, 1988;
Kolin, 1995; Pezzella et al, 1996, 1997, 2000; Offersen et al,
2001) that both lung primaries and secondaries can be divided into
two groups, one of which shows no histological evidence of neo-
angiogenesis. A pattern of non-angiogenic growth has also been
described in glioblastoma multiforme (Wesseling et al, 1994).
Hyjek et al (1999) have also reported a remarkably low number
of immature vessels in indolent lymphomas compared to the
increased number of newly formed vessels in high grade lympho-
mas.
We have reported that lung carcinomas without angiogenesis are
characterized by lack of parenchymal destruction and absence of
new vessels and tumour associated stroma. The only vessels present
appear to be those in the alveolar septa and their presence high-
lights, throughout the whole tumour, the lung alveoli ﬁlled up
by the neoplastic cells. In a ﬁrst study, clinico-pathological correla-
tion suggested that these tumours are highly aggressive (Pastorino
et al, 1997) though a subsequent study (Offersen et al, 2001)
suggests that this is not the case and that these tumours are prob-
ably less aggressive than initially thought. However, in both papers
the conﬁdence intervals of the relative risk for patients with non-
angiogenic tumours are very wide leaving the problem of the prog-
nosis of these tumours open. Because of their ability to exploit pre
existing vessels and the lack of neo-angiogenesis, these tumours are
likely to have some major biological differences from angiogenic
neoplasms. However, our observation was based on morphological
observations and only suggests, but does not demonstrate, that
some tumours could grow without the presence of newly formed
vessels.
Three recent studies (Nagano et al, 1993; Holash et al, 1999a,b)
further support the hypothesis that some tumours could grow by
exploiting pre-existing vessels. Vessel cooption has also been
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www.bjcancer.comdescribed in uveal melanoma (Maniotis et al, 1999). In the same
study the authors propose that in this type of melanoma also a
different type of angiogenesis-independent neoplastic growth
named ‘vasculogenic mimicry’, occurs. In vasculogenic mimicry;
the same melanoma cells would form ‘channels’ within the tumour
compartment.
Further investigation is required to establish whether there is a
type of tumour truly able to exploit pre-exiting vessels and grow
in the absence of angiogenesis. There are several possible
approaches to resolve this issue such as the use of ‘in vitro’ angio-
genic assays and in-situ detection of angiogenic factors. In this
study we have chosen to investigate the basic phenotype character-
istics of both the intra-tumour and normal lung vessels. Our aim
was to establish whether the vessels present in putative non-angio-
genic tumours have a ‘mature’ phenotype, as in the normal lung,
or an ‘immature’ phenotype as in angiogenic tumours.
To distinguish between mature and immature vessels we looked
at the expression or loss of two markers. The ﬁrst marker is an
epitope within the lamina lucida of the basement membrane of
human tissues (Almeida et al, 1992a) identiﬁed by the antibody
LH39. This molecule is expressed on the basal membrane of capil-
laries and small venules in a variety of normal human tissues but it
is absent in small vessels present in pyogenic granulomas or non-
speciﬁc oral ulceration (Almeida et al, 1992a,b). Furthermore,
Kakolyris et al (2000) have demonstrated that in normal breast
tissue (an organ in which remodelling occurs physiologically) a
proportion of the vessels is LH39 negative. These data suggest that
the detection of LH39 allows the discrimination between mature
and recently formed vessels. Most of the intra-tumoural vessels
should therefore be negative for LH39 and three studies, on oral
carcinomas (Almeida et al, 1992b), on breast carcinomas (Kakolyris
et al, 2000) and on lung cancer (Kakolyris et al, 1999) have
conﬁrmed this hypothesis. Even in the case of breast cancer, the
number of LH39-negative intra-tumoural vessels is signiﬁcantly
higher than in normal breast tissue (where some LH39 negative,
immature vessels are present because of the physiological remodel-
ling of the tissue).
The other marker we looked at, on the endothelium, is the
integrin aVb3. We looked at it mainly for two reasons.
The ﬁrst one is that aVb3 has been reported to be expressed on
newly formed endothelium (Brooks et al, 1994) but some authors
disagree (Rabb et al, 1996; Navratil et al, 1997; Pazouki et al, 1997):
they have demonstrated its expression also on a variety of normal
tissues. Therefore we wanted to establish whether in the lung aVb3
was expressed only in intra-tumour vessels or also in normal tissue
vessels. Eventually we wanted to establish whether the aVb3 pattern
of expression in putative non-angiogenic tumours was like the one
present in normal lung or in lung carcinomas.
The second reason is that Friedlander et al (1995) have
described also an aVb3-independent angiogenic pathway. Therefore
while the uniform expression, or non-expression, on intra-tumour
vessels of aVb3 could suggest the activation of just one angiogenic
pathway, the mixed presence of aVb3 positive and negative imma-
ture vessels would argue in favour of different pathways
simultaneously activated.
We also attempted to investigate the expression on the endothe-
lium of aVb5 which is expressed in newly formed endothelium in
an alternative fashion to aVb3 (Friedlander et al, 1995). However,
aVb5 turned out to be too widely expressed making the evaluation
of endothelial staining unreliable (data not shown).
MATERIAL AND METHODS
Tissue samples
Tissue samples from 113 patients were available. All patients had a
diagnosis of non-Small Cell Lung Carcinoma (n-SCLC) and had
undergone radical surgical resection either in Rome (Department
of Thoracic Surgery, Catholic University) or in London (Department
of Thoracic Surgery, Royal Brompton Hospital). Fresh tissue was
snap frozen in liquid nitrogen. For all cases the diagnosis was estab-
lished on routinely formalin-ﬁxed parafﬁn-embedded material.
Five samples of normal lung tissue were also obtained either
from lung parenchyma away from the tumour (three samples) or
from patients undergoing lung resection for emphysema (two
samples).
The tumours were classiﬁed as angiogenic (basal, papillary or
diffuse patterns) and non-angiogenic (alveolar pattern) as
previously described (Pezzella et al, 1997).
Immunocytochemistry
The following antibodies were used: the anti-CD31 JC70 mono-
clonal antibody (Parums et al, 1990) staining endothelial cells, the
anti lamina lucida antigen LH39 antibody (Almeida et al, 1992a)
and the anti aVb3 antibody LM609 (Chemicon International).
All immunostaining was performed on frozen tissue sections.
For single immunostaining the primary antibody was incubated
for 1 h at room temperature. Labelling was performed with an
avidin-biotin peroxidase labelling system (DAKO Duet). The
appropriate secondary antibody was applied for 35 min, after
which the DAKO streptavidin-biotin complex was applied. Finally,
application of DAB solution developed the staining reaction.
The double immunostaining, using the anti CD31 and anti LH39
antibodies, was performed as follows. Firstly the anti LH39 antibody
was incubated for 1 h at room temperature. Labelling was performed
with an avidin-biotin peroxidase labelling system (DAKO Duet). The
appropriate secondary antibody was applied for 35 min, after which
the DAKO streptavidin-biotin complex was applied. Application of
DAB solution developed the staining reaction. After rinsing, the
sections were incubated overnight with anti CD31. After further
rinsing sections were incubated with rabbit-anti-mouse immunoglo-
bulin and ﬁnally with APAAP complexes.
Evaluation of tumour vascularity
To evaluate the proportion of mature vessels, 200 vessels were
counted in each slide on which double immunostaining for
CD31 and LH39 had been carried out. The Vascular Maturation
Index (VMI), deﬁned as the percentage of vessels with LH39 posi-
tive basal membrane (Kakolyris et al, 1999), was then calculated.
On a similar basis we derived an Immaturity Index in order
to compare vessels positive for aVb3 to all the CD31 positive
vessels. In order to make a direct comparison, staining was
undertaken on serial sections and the count for CD31 on a
section was related to the count for aVb3 in the same areas
on the serial section. In this case the index indicates the per cent
of the immature vessels, i.e. aVb3 positive, of the total of CD31
positive vessels.
Numerical evaluation of vascular phenotype in the
angiogenic tumours
Because of the small numbers involved a statistical tool as such is
not employed here. Descriptive analysis is used with appropriate
numerical and graphical manipulation of the available data. For
the tumours where double staining was achieved and a readable
immunostaining for aVb3 was obtained, the percentages of LH39
positive and aVb3 positive were considered separately.
RESULTS
Histological diagnosis and vascular patterns
All 113 patients were diagnosed with n-SCLC. After staining for the
endothelial marker CD31, nine cases were classiﬁed as putative
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accounted for 8.6% of the total cases. This frequency is consistent
with the frequencies described so far in two other series: 16%
(Pezzella et al, 1997) and 12% (Offersen et al, 2001).
Evaluation of the vascular phenotype
Normal lung Normal lung from neoplastic and non-neoplastic
patients showed positive staining of the basal membrane for
LH39. The staining of endothelial cells with anti aVb3 antibodies
was variable with the endothelial cells in some cases being negative
but in others weakly or even strongly positive (Figure 1).
Non-angiogenic tumours In the nine putative non-angiogenic
cases investigated, all the intratumoral vessels showed a basal
membrane positive for LH39. The endothelial cells were negative,
weakly stained or even focally strongly positive, with anti aVb3
antibody, in a fashion similar to that observed in normal lung
(Figure 2).
Angiogenic tumours Heterogeneity of newly formed vessels: In all,
104 cases of angiogenic carcinomas were studied. In 102 cases
double immunostaining for CD31 and LH39 was obtained while
a readable immunostaining for aVb3 was obtained in only 44 cases.
In total, staining for all antibodies was assessable in 42 angiogenic
tumours.
If the hypothesis is true that the growth of newly formed vessels
(LH39 negative) is dependent on the expression of aVb3, then the
two percentages should complement each other in that their case-
wise sum should be 100. In other words all the LH39 negative
vessels would be aVb3 positive.
The immunostaining patterns of a typical angiogenic tumour
are seen in Figure 3. The average percentage of LH39 positive
(mature) intra-tumoural vessels is 12.9% (range 0–60%) while
the average percentage of aVb3 positive (newly formed) vessels
is 54% (range 5–90%). In Figure 4 the percentages of mature
(LH39 positive) vs immature (deﬁned as aVb3 positive) are
plotted. An inverse correlation is expected if the assumption that
all the newly formed vessels are aVb3 positive is true. It is
obvious that the hypothesis does not hold for the whole of the
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Figure 1 Normal lung (frozen sections). (A)( 6400) Double immuno-
staining for LH39 (in brown) and CD31 (in blue); no counterstaining was
done. The vessels of the alveolar walls have LH39 expression in their
membrane. (B)( 6400) Staining for aVb3 (in brown). The nuclei are coun-
ter stained with haematoxilin (blue). A variable positivity on the endothelial
cells is present.
Figure 2 A non-angiogenic tumour (frozen sections). (A)( 6100) (low magniﬁcation) and (B)( 6400) double immunostaining for LH39 (in brown) and
CD31 (in blue); no counterstaining was done. All the vessels express LH39 in the basal membrane. (C)( 6100), (D)( 6400) Immunostaining for aVb3 (in
brown); the nuclei are counter stained with haematoxilin (blue). A variable positivity on the endothelial cells is present as seen in normal lung (Figure 1).
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tive) but do not express aVb3.
Closer observation (Figure 4) reveals that of 42 angiogenic carci-
nomas only 14 (group A) fulﬁl the theoretical criteria of a sum of
100% (that is about one third of the data set) whereas the majority
of the cases have a sum of 81% or less (groups B and C). In group
B (15 cases) the sum of vessels positive for LH39 and/or aVb3 was
between 5 and 75%. In the remaining 13 cases (group C) no LH39
staining was detected in the basal membrane of the vessels, but still
only a proportion was aVb3.
The angiogenic switch: This study of vessel phenotype highlights
that in 17 out of the cases investigated, a residual component of
pre-existent vessels is seen in addition to neo-angiogenesis.
In 14 cases out of these 17 tumours, the tumour had a predo-
minant angiogenic pattern classiﬁed as basal according to our
described criteria (Pezzella et al, 1997), however the outer area of
the neoplastic nodule shows that the neoplastic cells are exploiting
the pre-existing alveolar vessels (CD31 and LH39 positive). Deeper
in the tumour the alveolar walls appear to become oedematous,
inﬁltrated by lymphocytes and macrophages. Among them numer-
ous immature microvessels, negative for LH39, are present (Figure
5).
A different pattern of angiogenic switch is instead observed in
the remaining three cases of tumours. These cases had a papillary
pattern (Pezzella et al, 1997). However the papillary component
accounts for the minority of the tumour so we have termed it
‘early papillary’. As shown in Figure 6, the columnar cells of these
three cases grow along CD31 and LH39 positive alveolar vessels.
However, within some alveolar spaces, small buds of neoplastic
cells occur with a central ﬁbrous core in which LH39 negative
aVb3 positive vessels are present.
DISCUSSION
The relationship between tumour and vessels is a complex one. As
it happens frequently, diverse experimental evidence has been
produced supporting apparently contradictory hypotheses, which
may all be partly true but in a wider and more complex context
than initially thought. An early hypothesis stated that tumours
were associated with pre-existing vessels (Coman and Sheldon,
1946; Warren, 1979). Later robust experimental evidence (for
review see Folkman, 1995) was produced illustrating the funda-
mental role of new vessel formation in neoplastic growth.
However, the model that neo-angiogenesis is necessary for a
tumour to become larger than a few millimetres, and hence
become clinically detectable, does not appear to hold for all
tumours.
The present study has produced two main results: the ﬁrst
concerns the phenotype of the intra-tumoural vessels in the non-
angiogenic tumours, the second the phenotype of the vessels in
the angiogenic tumours. As far as the ﬁrst point is concerned we
wanted to establish whether in some primary lung tumours in
which there is no morphological evidence of neo-angiogenesis,
the vessels have a phenotype comparable to that of the vessels
present in normal lung or to that of newly formed vessels. Having
characterized the intra-tumoural vessels using the LH39 and aVb3
markers, we found a clear result: the vessels present in the putative
non-angiogenic lung carcinomas not only have the same architec-
tural pattern, but also the same phenotype, as those present in
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Figure 4 Phenotype of intratumour vessels in 44 angiogenic lung
n-SCLC. Three groups of tumours can be identiﬁed. Groups A (diamonds)
and B (triangles) are made up of a mixture of mature (LH39 positive) and
immature (LH39 negative) vessels. However while in group A all the imma-
ture express aVb3, in group B the immature are, in part, aVb3 negative.
Group C (circles) is made up almost completely by new vessels (LH39
negative) but only a proportion are aVb3 positive. N.B.: each symbol in
the diagram may well represent more than one sample.
Figure 5 Angiogenic tumour, basal pattern with residual non angiogenic
component (frozen sections). Double immunostaining for LH39 (in brown)
and CD31 (in blue), no counter staining was done. (A)( 6100) In some
areas an alveolar pattern is still present. The arrows indicates where
tumour-associated stroma is present and where remodelling and angiogen-
esis start. (B)( 6400) Islands of neoplastic cells survive surrounded by
stroma with new vessels.
Figure 3 An angiogenic lung carcinoma (frozen sections). (A)( 6400)
double immunostaining for LH39 (in brown) and CD31 (in blue) no coun-
ter staining was done. Only a few vessels express LH39 in the basal
membrane. (B)( 6400) Immunostaining for aVb3 (in brown). The nuclei
are counter stained with haematoxilin (blue). Some vessels are strongly
stained.
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type in these tumours.
While our data conﬁrm the novel ﬁnding that some tumours
can grow to clinically detectable dimensions in the absence of
angiogenesis, they also conﬁrmed some observations previously
reported in the literature regarding the vascular phenotype of
normal vessels. We conﬁrmed (Almeida et al, 1992a) that vessels
of the normal lung express LH39 in their basal membrane. In
contrast staining for aVb3 was not an absolute marker of newly
formed vessels. While it is well established that endothelial expres-
sion of aVb3 is essential for angiogenesis induced by basic
ﬁbroblastic growth factor or tumour necrosis factor a (Brooks et
al, 1994; Friedlander et al, 1995), it has also been found that it
can be up-regulated in resting endothelium (Tang et al, 1994).
Studies in normal human tissue have shown that endothelium is
negative for aVb3 in breast (Gasparini et al, 1998) while in normal
brain, skin and kidney the endothelial cells express it to various
degrees (Rabb et al, 1996; Navratil et al, 1997; Pazouki et al,
1997). It is arguable whether this is due to the nearby tumour:
we observed the same pattern in normal lung from neoplastic
and non-neoplastic patients.
Our second set of results is concerned with the vascular pheno-
type in angiogenic tumours. In all the cases classiﬁed as angiogenic
we have conﬁrmed that most of the vessels have an immature
phenotype, with deﬁcient LH39 expression, as observed previously
in oral carcinoma (Almeida et al, 1992b), breast carcinoma (Kako-
lyris et al, 2000), and another series of n-SCLC (Kakolyris et al,
1999). It should be noted that a variable number of mature vessels
is still present.
Furthermore, we showed that in a number of cases, the newly
formed vessels are likely to be driven by at least two pathways:
one being dependent on aVb3 and the other being independent.
Such a heterogeneity raises a question concerning the response to
anti-angiogenic treatment: within the same tumours some vessels
would respond to such treatments (e.g. the humanized anti aVb3
antibody Vitaxin (Gutheil et al, 2000) whilst others would not.
A ﬁnal point concerns the topographical localization of where
in the tumour the angiogenic switch could occur. This is now
made possible by the ability to distinguish recently formed
vessels from pre-existent ones. Whilst discussing the angiogenic
switch Hanahan and Folkman (1996), raised the following ques-
tions:
. When is angiogenesis activated during the development of a
tumour?
. Is angiogenesis simply an inevitable consequence of any nodules
of aberrant proliferating cells becoming size-limited by lack of
vascularization or is it a discrete component of the tumour
phenotype?
As far as the ﬁrst question is concerned, Hanahan and Folkman
(1996) showed convincing evidence that both in experimental
murine and in human tumours there was a dramatic difference
in microvessel density between early hyperplasia and neoplastic
transformation. These observations indicated that the angiogenic
switch occurs at an early stage of tumour growth. Studies of
human tumours (breast, cervix and lung) indicate that the occur-
rence of high microvessel density is detected in association with
carcinoma in situ and precedes the occurrence of inﬁltration. In
contrast the patterns of vessel distribution that we observed
suggest that in some circumstances angiogenic switching can
occur at a later stage, further demonstrating that in these tumours
the angiogenic switch is not necessary for the tumour itself to
grow. This is not surprising in view of our other ﬁnding that
some tumours can grow without any angiogenesis at all. Further-
more, the delayed occurrence of the angiogenic switch has been
shown to occur in a rat model by Holash et al (1999a). These
observations raise the question of why in these tumours angiogen-
esis is occurring at all.
This point brings us to the second question raised by Hanahan
and Folkman (1996): is the angiogenic switch just a step necessary
for the neoplastic growth or is it a discrete component in the
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Figure 6 Early papillary pattern (frozen sections). (A)( 640) Double immunostaining for LH39 (in brown) and CD31 (in blue). No counter staining was
done. The alveolar pattern appears preserved throughout the tumour. (B)( 6100) Haematoxilin and Eosin (C)( 6100) CD31 (in brown, the nuclei are
counter stained with haematoxilin (blue)) and (D)( 6100) CD34 (in brown, the nuclei are counter stained with haematoxilin (blue)). Within these micro-
papillae a small vessel (arrow), positive for CD31 and CD34, is present. (E)( 6100) Double immunostaining for LH39 (in brown) and CD31 (in blue). No
counter staining was done. A new vessel CD31 positive but LH39 negative (arrow) is present in the stalk of this micropapilla. (F)( 6100) Staining for aVb3
(in brown). The nuclei are counter stained with haematoxilin (blue). An aVb3 positive microvessel (arrow) within an early papilla.
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carcinomas and in adenocarcinomas of the lung, the switch can
occur when the tumour is already expanding, further supports
the conclusion of Hanahan and Folkman (1996) that the angio-
genic switch is a discrete component of the tumour phenotype.
Whether primary lung non-angiogenic tumours are more
aggressive than angiogenic tumours is debated (Pastorino et al,
1997; Offersen et al, 2001) but they appear to be anyway fairly
aggressive tumours and vessels could still play a key role. The
normal vessels trapped in the tumour could be more effective than
the newly formed for several reasons. They could allow the tumour
to growth efﬁciently by exploiting the highly regular vascular
network of the lung and progressing by ﬁlling the empty alveolar
spaces. Lung vessels also offer a ‘vascular window’ which can prob-
ably favour neoplastic spread.
We have also described lung metastases with a non-angiogenic
tumour appearing after a long disease-free interval (Pezzella et al,
2000). This implies that neoplastic cells could escape dormancy
even if angiogenesis is still suppressed.
Finally the ﬁnding that primary and secondary tumours can be
non-angiogenic raises the issue of potential resistance to anti-
angiogenic treatments and highlights the need for tailor-made
treatments against such tumours.
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